- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04258072
Vactosertib With Nal-IRI/FL in Metastatic Pancreatic Ductal Adenocarcinoma.
June 13, 2022 updated by: Joon Oh Park, Samsung Medical Center
Phase 1b Study of Vactosertib (TEW-7197) in Combination With Nal-IRI/FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine/Nab-Paclitaxel
To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel
Study Overview
Detailed Description
- Number of patients : Total 24 patients (6-12 patients in phase 1 part and 12 patients in expansion cohort )
Treatment :
- Vactosertib* 100-300 mg bid for 5 days
- Liposomal Irinotecan (Onivyde) 70mg/m2 on D1
- LV 200mg/m2 IV bolus on D1
5-FU 2400mg/m2 CIV over 46 hours on D1
- Vactosertib will be kindly provided by MedPacto.
- Disease evaluation: Tumor assessment will be conducted at screening and before Day 1 of every third cycle starting with Cycle 4
- Period : Approximately 24 months from the date of Institutional Review Board (IRB) approval
- Primary endpoint : To determine recommended phase 2 dose and to evaluate the safety of vactosertib in combination with nal-IRI/FL in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) who have failed first-line gemcitabine and nab-paclitaxel
Secondary endpoint :
- Progression-Free Survival (PFS) (RECIST 1.1 criteria)
- Overall Survival (OS)
- Objective Response Rate (ORR) (RECIST 1.1 criteria)
- Disease Control Rate (DCR) (RECIST 1.1 criteria)
Exploratory endpoint
- Pharmacokinetic assessment: before treatment, post treatment 1.5h, 4.5h, and 8hPharmacodynamic assessment: to evaluate changes in the amount of p-SMAD in PBMC.
- Biomarker analysis in pre-treated and post-treated tumor samples
Study Type
Interventional
Enrollment (Anticipated)
24
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Recruiting
- Samsung Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
17 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Subjects who are males or females ≥ 19 years of age
- Subjects who have the following history of first-line gemcitabine-based chemotherapy among patients with cytologically or histologically proven metastatic pancreatic ductal adenocarcinoma
- Subjects who can give written informed consent for participation in this trial after receiving explanations of this trial
Subjects who have the following laboratory test values:
- bilirubin ≤ 1.5 x ULN (upper limit of normal)
- aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x ULN
- serum creatinine ≤ 1.5 x ULN or estimated creatinine clearance ≥ 40 mL/min (Cockcroft-Gault)
- partial thromboplastin time (aPTT) ≤ 1.5 x ULN
- absolute neutrophil count (ANC) ≥ 1,500 cells/µL
- platelet count ≥ 100,000/µL
- hemoglobin ≥ 9.0 g/dL
- Subjects who have at least a 12-week life expectancy at the Investigator's discretion
- Subjects who have Eastern Cooperative Oncology Group (ECOG)Performance Status 0-1
Exclusion Criteria:
- Subjects who were treated with surgery, radiotherapy, chemotherapy or investigational therapy within 2 weeks (note: placement of biliary stent is allowed)
- Subjects who have uncontrolled CNS metastases (patients who require steroids should be on a stable or decreasing dose for at least 2 weeks)
- Subjects who have any contraindications for 5-FU, leucovorin, or nal-IRI
Subjects who have moderate or severe cardiovascular disease
- Subjects who have myocardial infarction, unstable angina pectoris, New York Heart Association (NYHA) Class III/IV congestive heart failure, or uncontrolled hypertension within 6 months before screening
- Subjects who have major abnormalities at the Investigator's discretion based on electrocardiogram (ECG)and Doppler ECHO results at screening or within 14 days before screening
- Subjects who have increase in brain natriuretic peptide (BNP) or increase in troponin (over 99th percentile upper reference limit) at Screening (based on the normal range of relevant study center)
- Subjects who have risk factors for ascending aortic aneurysm such as genetic disorder and trauma and risk factors for aortic stenosis
- Subjects who have a history of heart or aorta surgery
- Subjects who have clinically significant gastrointestinal bleeding within 4 weeks before screening
- Subjects who have a known history or suspected hypersensitivity to any excipients of the investigational product or combination drug(s)
- Subjects who have received prior treatment targeting the signaling pathway of TGF-β
Subjects who have a disease or condition that affects the mechanism of the investigational product, or are currently using or planning to use:
- Drugs that are exclusively or primarily eliminated by cytochrome P-450 isozyme (CYP) including CYP1A2, CYP2B6, or CYP3A4
- Drugs that are exclusively or primarily eliminated by UDP glucuronyltransferase (UGT) 1A1 (UGT1A1)
- Drugs that are substrates for the drug transporter multidrug resistance protein 1 (MDR1) have a narrow therapeutic window or are strong inhibitors of drug transporter MDR1
- Drugs that are strong inhibitors or inducers of CYP2D6 or CYP3A4
- Subjects who are unable to swallow tablets
- Subjects who have a history of or are suspected of drug abuse
- Female subjects of child-bearing potential who have a positive result on a pregnancy test at screening or are unable to agree to use an effective barrier method of birth control to avoid pregnancy during the study period (e.g., sterilization, intrauterine contraceptive device, combination of oral contraception and barrier contraception, combination of other hormone delivery systems and barrier contraception, contraceptive cream, combination of cream, jelly, or form and diaphragm or condom)
- Subjects, in the opinion of the Investigator, who are unsuitable to participate in the study
- Subjects who were treated with other investigational products within 28 days before screening or within a period shorter than 5-timesthe half-life of the investigational product
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: open label,single arm
Vactosertib* 100-300 mg bid for 5 days + Liposomal Irinotecan (Onivyde) 70mg/m2 + LV 200mg/m2 IV bolus + 5-FU 2400mg/m2 CIV over 46 hours
|
Vactosertib: 50-mg white round film-coated tablets containing excipients (lactose monohydrate Fastflo 316, microcrystalline cellulose Avicel PH 102, crospovidone Kollidon CL-F, povidone Kollidon 30, magnesium stearate, opadry white) and active pharmaceutical ingredient (N-((4-([1,2,4]triazolo[1,5-a]pyridin-6-yl)-5-(6-methylpyridin-2-yl)-1H-imidazol-2-yl)methyl)-2-fluoroaniline), 10% (w/w) of total weight
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Progression-Free Survival (PFS)
Time Frame: up to 6 weeks
|
up to 6 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 19, 2021
Primary Completion (Anticipated)
December 1, 2022
Study Completion (Anticipated)
March 1, 2023
Study Registration Dates
First Submitted
January 21, 2020
First Submitted That Met QC Criteria
February 3, 2020
First Posted (Actual)
February 6, 2020
Study Record Updates
Last Update Posted (Actual)
June 15, 2022
Last Update Submitted That Met QC Criteria
June 13, 2022
Last Verified
June 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2019-10-054
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreas Cancer
-
Washington University School of MedicineCompletedPancreatic Cancer | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the PancreasUnited States
-
Joseph J. CullenNational Cancer Institute (NCI); National Institutes of Health (NIH); Holden... and other collaboratorsActive, not recruitingAdenocarcinoma | Pancreatic Neoplasms | Pancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Emory UniversityCompletedPancreas Cancer | Pancreas Neoplasms | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Washington University School of MedicineNational Cancer Institute (NCI); BioMed Valley Discoveries, IncTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
National Cancer Institute (NCI)CompletedPancreatic Neoplasms | Pancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the PancreasUnited States
-
BioXcel Therapeutics IncIQVIA BiotechWithdrawnPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas | Neoplasms, PancreaticUnited States
-
Baylor Research InstituteUnknownPancreas Cancer | Localized Pancreas Cancer | Non-metastatic Pancreas CancerUnited States
-
AmgenTerminatedPancreatic Cancer | Pancreas Cancer | Cancer of Pancreas | Cancer of the Pancreas
-
Newcastle-upon-Tyne Hospitals NHS TrustMedtronicCompletedPancreas Adenocarcinoma | Chronic Pancreatitis | Pancreas Cancer | Pancreas Neoplasm, BenignUnited Kingdom
-
NantCell, Inc.TakedaTerminatedCancer | Pancreatic Cancer | Advanced Solid Tumors | Metastatic Cancer | Bone Metastases | Solid Tumors | Pancreas Cancer | Adenocarcinoma of the Pancreas | Oncology | Cancer of Pancreas | Metastatic Pancreatic Cancer | Metastases | Cancer of the Pancreas | Advanced Malignancy | Oncology Patients | Endocrine CancerItaly, Spain, United Kingdom, Belgium, Canada, Denmark, Romania, United States, Germany, Netherlands, Korea, Republic of, Russian Federation, Australia, Austria, Lithuania, Portugal, Greece, Poland, Switzerland, Serbia, Bulgaria, ... and more
Clinical Trials on Vactosertib
-
MedPacto, Inc.CompletedHealthy VolunteersKorea, Republic of
-
Hyo Song KimActive, not recruitingDesmoid TumorKorea, Republic of
-
MedPacto, Inc.Merck Sharp & Dohme LLCActive, not recruitingMetastatic Colorectal Cancer | Gastric Cancer | Gastroesophageal Junction AdenocarcinomaKorea, Republic of
-
MedPacto, Inc.Active, not recruitingMetastatic Gastric CancerKorea, Republic of
-
Yonsei UniversityNot yet recruitingMucosal Melanoma | Acral MelanomaKorea, Republic of
-
MedPacto, Inc.AstraZenecaNot yet recruitingUrothelial Carcinoma Recurrent | Advanced Urothelial CarcinomaUnited States
-
Hark Kyun KimRecruiting
-
Weill Medical College of Cornell UniversityRecruitingMyeloproliferative NeoplasmUnited States
-
MedPacto, Inc.RecruitingOsteosarcomaUnited States, Korea, Republic of